risdiplam
Sign in to saveAlso known as RG7916, RO7034067
Risdiplam, sold under the brand name Evrysdi, is a medication used to treat spinal muscular atrophy (SMA) and is the first oral medication approved to treat this disease by the US Food and Drug Administration (FDA).
Key facts
- Drug.image
- Risdiplam.svg
- Drug.image_class
- skin-invert-image
- Drug.tradename
- Evrysdi
- Drug.DailyMedID
- Risdiplam
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- M09
- Drug.ATC_suffix
- AX10
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.CAS_number
- 1825352-65-5
- Drug.PubChem
- 118513932
- Drug.DrugBank
- DB15305
- Drug.ChemSpiderID
- 67886354
- Drug.UNII
- 76RS4S2ET1
- Drug.KEGG
- D11406
via Wikipedia infobox
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 401.1964083560002
Show 3 more facts
- canonical SMILES
- CC1=CC(=NN2C1=NC(=C2)C)C3=CC(=O)N4C=C(C=CC4=N3)N5CCNC6(C5)CC6
- chemical formula
- C₂₂H₂₃N₇O
- Commons category
- Risdiplam
Sources (2)
via Wikidata · CC0
~5 min read
Encyclopedic overview
12 sectionsContents
- Medical uses
- Adverse effects
- Pharmacology
- Mechanism of action
- Efficacy
- Society and culture
- Legal status
- Names
- Compassionate use
- References
- Further reading
- External links
Risdiplam, sold under the brand name Evrysdi, is a medication used to treat spinal muscular atrophy (SMA) and is the first oral medication approved to treat this disease by the US Food and Drug Administration (FDA).
Risdiplam is a survival of motor neuron 2-directed RNA splicing modifier.
Excerpted from Wikipedia’s “risdiplam” article, available under the CC BY-SA 4.0 licence.